Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study

ObjectivesEvaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs.DesignInternational, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boards.S...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ open 2023-04, Vol.13 (4), p.e064159-e064159
Hauptverfasser: Boisvert-Huneault, Christian, Trigos Herraez, David, Pinter, Andreas, Kobayashi, Satomi, Bell, Stacie, Kallsen, Kimberley, Gloede, Tristan, Yagi, Nobutaka, Brunette, Steven, Datsenko, Yakov, Baehner, Frank, Clerisme-Beaty, Emmanuelle, Van de Kerkhof, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ObjectivesEvaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs.DesignInternational, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boards.SettingVirtual clinic visits and accompanying advisory boards.ParticipantsNine patients with palmoplantar pustulosis for simulated trial visits; 14 patients and patient representatives for advisory boards.Main outcome measuresQualitative responses to trial documentation, visit schedule and logistics, and trial design were collected during patient debriefs. Results were discussed at two virtual advisory board meetings.ResultsPatients identified key barriers to participation and potential difficulties encountered when attending trial visits and completing assessments. They also proposed recommendations to overcome these challenges. Patients recognised the need for comprehensive informed consent forms, but recommended use of non-technical language, brevity and additional support to aid understanding. Other trial documentations should be relevant to the disease and include known efficacy and safety of the study drug. Patients were concerned about receiving placebo, stopping existing medications and being unable to receive the study drug after trial completion; therefore, patients and physicians recommended an open-label extension following trial completion. Trial visits were too numerous (n=20) and too long (3–4 hours each); patients recommended improvements to the design to make best use of their time and reduce unnecessary waiting. They also requested financial and logistical support. Patients expressed a desire for study outcomes that matter to them, related to their ability to undertake normal daily activities and not be a burden to others.ConclusionsSimulated trials are an innovative method for assessing trial design and acceptance from a patient-centric perspective, enabling specific improvements to be made prior to trial initiation. Incorporation of recommendations from simulated trials could enhance trial recruitment and retention, and optimise trial outcomes and data quality.
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2022-064159